Adamkova Krakorova D, Vesely K, Zambo I, Tucek S, Tomasek J, Jureckova A, Janicek P, Cerny J, Pazourek L, Ondrusek S, Selingerova I
Klinika komplexni onkologicke pece, MOU Brno.
Klin Onkol. 2012;25(5):346-58.
The objective of this report was to estimate long-term outcome and prognostic factors in adult patients with high-grade osteosarcoma. The intended therapeutic strategy included preoperative and/or postoperative chemotherapy as well as surgery of all operable lesions.
We reviewed the clinical data of 36 newly diagnosed adult patients (aged 19-82, average 37.5, median 28.5 years) with high-grade osteosarcoma of the trunk or limbs evaluated by a multidisciplinary team and treated between 1999 and 2010 in Brno. Forty-five percent of patients were over thirty, more than 36% over forty. Thirty-one percent of patients had metastasis at the time of diagnosis. Demographic parameters, tumor-related and treatment-related variables included possible prognostic factors and their impact on response, overall survival (OS) and event-free survival (EFS) were analyzed.
All the patients were followed up after treatment. Seventy-three percent of patients were poor responders to chemotherapy. Sixteen patients are alive, and twenty patients died. The survival time ranged from 2 to 177 months (average 45 months, median survival 23 months). The 5-year OS of all patients was 52.4%. OS of patients without metastasis was 68.12%, while 2-year OS with metastasis was 26% only. 5-year EFS was 38.7%. Univariate analysis revealed that the prognosis of adult osteosarcoma patients was significantly related to distant metastasis (p = 0.006), surgical stage (p = 0.00582), serum alkaline phosphatase (ALP) level (p = 0.00841) and serum lactatdehydrogenase (LD) level (p = 0.047). The other analyzed prognostic factors including age had no statistically significant influence on outcome of osteosarcoma in adult patients.
The prognosis of osteosarcoma in adult patients was significantly correlated to surgical stage, distant metastasis, serum ALP and LD.
本报告的目的是评估成年高级别骨肉瘤患者的长期预后及预后因素。预期的治疗策略包括术前和/或术后化疗以及对所有可手术病变进行手术。
我们回顾了1999年至2010年在布尔诺由多学科团队评估并治疗的36例新诊断的成年躯干或四肢高级别骨肉瘤患者(年龄19 - 82岁,平均37.5岁,中位年龄28.5岁)的临床资料。45%的患者年龄超过30岁,超过36%的患者年龄超过40岁。31%的患者在诊断时已有转移。分析了人口统计学参数、肿瘤相关和治疗相关变量,包括可能的预后因素及其对反应、总生存期(OS)和无事件生存期(EFS)的影响。
所有患者治疗后均进行了随访。73%的患者对化疗反应不佳。16例患者存活,20例患者死亡。生存时间为2至177个月(平均45个月,中位生存期23个月)。所有患者的5年总生存率为52.4%。无转移患者的总生存率为68.12%,而有转移患者的2年总生存率仅为26%。5年无事件生存率为38.7%。单因素分析显示,成年骨肉瘤患者的预后与远处转移(p = 0.006)、手术分期(p = 0.00582)、血清碱性磷酸酶(ALP)水平(p = 0.00841)和血清乳酸脱氢酶(LD)水平(p = 0.047)显著相关。其他分析的预后因素包括年龄,对成年骨肉瘤患者的预后无统计学显著影响。
成年骨肉瘤患者的预后与手术分期、远处转移、血清ALP和LD显著相关。